Skip to main content

Table 1 Age-adjusted incidence rates and incidence rate ratios of small cell lung carcinoma and extrapulmonary small cell carcinoma according to primary site and gender, SEER-13, 1992-2010*

From: A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010

 

ICD-O-3

Males

Females

Male-to-female

Site

topography codes

No.

IR

No.

IR

IRR

(95 % CI)

Total§

00.0-80.9

28,820

96.20

26,902

71.44

1.35

(1.32, 1.37)†

SCLC

34.0-34.9

26,798

89.19

25,161

66.88

1.33

(1.31, 1.36)†

EPSCC

00.0-33.9, 35.0-75.9, 77.0-77.9

1,272

4.41

1,166

3.06

1.44

(1.33, 1.56)†

Salivary glands

07.9-08.9

44

0.16

<16

~

~

 

Esophagus

15.0-15.9

106

0.36

81

0.21

1.72

(1.27, 2.33)†

Stomach

16.0-16.9

64

0.21

24

0.06

3.46

(2.12, 5.80)†

Colon/rectum

18.0-20.9

125

0.42

113

0.30

1.41

(1.08,1.84)†

Anus

21.0-21.8

16

0.05

21

0.06

0.95

(0.46, 1.91)

Liver/intrahepatic bile ducts

22.0-22.1

18

0.06

<16

~

~

 

Gallbladder

23.9

<16

~

30

0.08

~

 

Pancreas

25.0-25.9

89

0.30

84

0.22

1.38

(1.01, 1.88)†

Nose, nasal cavity, middle ear

30.0-30.1, 31.0-31.9

21

0.07

16

0.04

1.56

(0.77, 3.21)

Larynx

32.0-32.9

37

0.11

27

0.07

1.57

(0.93, 2.68)

Breast

50.0-50.9

<16

~

68

0.18

~

 

Vagina

52.9

NA

NA

37

0.10

~

 

Cervix

53.0-53.9

NA

NA

260

0.69

~

 

Uterus

54.0-55.9

NA

NA

56

0.15

~

 

Ovary

56.9

NA

NA

111

0.29

~

 

Prostate

61.9

206

0.73

NA

NA

~

 

Kidney and renal pelvis

64.9, 65.9

22

0.07

<16

~

~

 

Urinary bladder

67.0-67.9

411

1.48

118

0.30

4.91

(3.99, 6.09)†

Unknown primary

76.0-76.8, 80.9

750

2.61

575

1.50

1.73

(1.55, 1.94)†

  1. Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, ICD-O-3 third edition of the International Classification of Diseases for Oncology, NA not applicable, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results Program, ~ IRs and IRRs are not calculated for <16 cases.
  2. *Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates.
  3. †95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).
  4. §Specified sites with 1–15 total cases not shown in the table (ICD-O-3 code): tongue (01.1-0.29), gum and other mouth (03.0-03.9, 05.0-05.9, 06.0-06.9), tonsil (09.0-09.9), oropharynx (10.0-10.9), hypopharynx (12.9, 13.0-13.9), other oral cavity and pharynx (14.0-14.8), small intestine (17.0-17.9), intestinal tract, unspecified (26.0-26.9), soft tissues, including heart (38.0, 47.0-47.9 49.0-49.9), retroperitoneum/peritoneum (48.0-48.8), vulva (51.0-51.9), other female genital (57.0-58.9), testis (62.0-62.9), other male genital (63.0-63.9), ureter (66.9), eye and orbit (69.0-69.9), thyroid (73.9), other endocrine (37.9, 74.0-74.9, 75.0-75.9), and lymph nodes (77.0-77.9). Sites with >15 cases, but with fewer than 16 among both, males and females, not specified in the table (No., IR, ICD-O-3 code): nasopharynx (No. = 23; IR = 0.03; 11.0-11.9), other biliary (No. = 19; IR = 0.03; 24.0-24.9), and trachea/mediastinum/other respiratory (No. = 25; IR = 0.04; 33.9, 38.1-39.9).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us